Provenance
Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
Templates available
Version 3.0 of this PGD template, valid from May 2026, has been published to allow organisations to undertake local governance processes in a timely manner.
Version 2.3 of this PGD template remains currently valid and will be removed from this page on its expiry (30th April 2026).
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice.
More reproductive health PGD templates
- Ulipristal acetate 30mg tablets for emergency contraception
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Combined hormonal contraceptive transdermal patch
- Combined hormonal contraceptive vaginal ring
- Progestogen only pill (POP) for contraception
- Lidocaine plus prilocaine cream for IUD insertion or removal
- Combined oral hormonal contraceptive (COC) in reproductive health
- Medroxyprogesterone acetate (DMPA) IM injection for contraception
- Lidocaine 10mg/ml spray for IUD insertion or removal
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Lidocaine injection for subdermal etonogestrel in contraception
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Copper Intrauterine Device (Cu-IUD)
All PGD templates
National PGD, protocol and written instructions templates
National templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.
Update history
- Revised template to reflect minor clarifications following feedback.
- Version 3.0 published
- Planned review detail added
- Information added regarding name change of FSRH to CoSRH
- Version 2.3 PGD template added. Updated contraindications and cautions in line with SmPC changes.
- Updated PGD template published - statement added regarding a suggested link between the prolonged use of medroxyprogesterone acetate and a small increased risk of intracranial meningioma in line with FSRH statement. Added exclusion of meningioma as per SPC.
- Version 2.1 published - minor changes to align with updated FSRH guidance
- Title, URL and summary amended.
- Expiring template removed.
- Version 2.0 PGD template added
- Published